ASMB

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company based in South San Francisco, California, dedicated to developing innovative therapies targeting viral infections and liver diseases, principally hepatitis B. The company’s proprietary core inhibitor technology underpins a robust pipeline of drug candidates designed to meet significant unmet medical needs in chronic infection treatment. With a strategic focus on transforming current treatment paradigms, Assembly Biosciences represents a compelling investment opportunity for institutional investors looking to capitalize on breakthroughs in the biopharmaceutical industry.